Publications by authors named "R Pataky"
Background And Objective: Mutations in KRAS and NRAS are predictive of poor response to cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies used in metastatic colorectal cancer (mCRC). Our objective was to explore the value of using KRAS and NRAS mutation status to inform third-line anti-EGFR therapy for mCRC using the value of heterogeneity (VOH) framework.
Methods: We used administrative data to identify mCRC patients who were potentially eligible for third-line therapy in 2006-2019 in British Columbia (BC), Canada.
Article Synopsis
- The SHAPE trial showed that simple hysterectomy is just as effective as radical hysterectomy in preventing pelvic recurrence in low-risk early-stage cervical cancer, but offers better quality of life and sexual health.
- A cost-effectiveness analysis using a Markov model over 5 years found that simple hysterectomy costs less ($11,022) and provides more quality-adjusted life years (3.56 QALYs) compared to radical hysterectomy ($12,533 and 3.54 QALYs).
- The study concluded that simple hysterectomy is a better option overall due to being more cost-effective and yielding a higher quality of life post-surgery.
Background: Mutations in KRAS and NRAS are associated with a lack of response to cetuximab and panitumumab, two biologics used for third-line therapy of metastatic colorectal cancer (mCRC). In British Columbia, Canada, eligibility for cetuximab or panitumumab was first based on single-gene KRAS testing. OncoPanel, a multi-gene next-generation sequencing panel with both KRAS and NRAS, was introduced in 2016.
View Article and Find Full Text PDFArticle Synopsis
- Niraparib has been recently funded in Canada for maintaining ovarian cancer treatment after chemotherapy, but its real-world safety remains unclear.
- A cohort study was conducted involving 514 patients across four Canadian provinces, analyzing their characteristics and adverse events when using niraparib from June 2019 to December 2022.
- Results showed that significant hematological issues like anemia, neutropenia, and thrombocytopenia affected 11-16% of patients, but these rates were relatively low, possibly due to careful prescribing and monitoring by healthcare providers.
Article Synopsis
- The Canadian Partnership Against Cancer aims to eliminate cervical cancer in Canada by 2040, focusing on increasing HPV vaccination, implementing HPV-based screening, and improving follow-up care after abnormal results.
- A microsimulation model, OncoSim-Cervical, was used to explore the effects of these priorities on cervical cancer elimination timelines specifically for British Columbia.
- Current HPV-based screening could eliminate cervical cancer by 2034, but with improved participation and follow-up, this could be accelerated to as early as 2031; enhancing vaccination has less of an impact on the timeline.